The potential for RPT has been exemplified by the somatostatin receptor (SSTR) and prostate-specific membrane antigen (PSMA) targeted radiopharmaceuticals, which have received Food and Drug Administration (FDA) approval for the treatment of patients with neuroendocrine and prostate tumors, respectively [16,18]. The gene discussed is FOLH1; the disease is prostate neoplasm.